Full-Time

Vice President Enterprise Architecture and Infrastructure

Posted on 7/30/2026

TransMedics

TransMedics

501-1,000 employees

Ex-vivo organ perfusion platform

Compensation Overview

$295.8k - $369k/yr

+ Bonus + Equity

Andover, MA, USA

In Person

Bachelor's, Master's, MBA

Category
DevOps & Infrastructure (1)
Required Skills
Microsoft Azure
ERP
Cybersecurity
Microservices
AWS
Observability
REST APIs
Data Governance
Google Cloud Platform

Get referred to TransMedics

See people who can refer or advise you

Requirements
  • 15+ years of IT leadership experience, including 5+ years in enterprise architecture and cloud infrastructure at the executive level.
  • Proven success leading global 24x7 software-as-a-service and cloud operations and large-scale data center environments.
  • Demonstrated experience implementing highly available, scalable, and secure enterprise systems across hybrid cloud and on-premises environments.
  • Expertise in cloud platforms such as Azure, Amazon Web Services, or Google Cloud, and modern infrastructure management tools.
  • Strong financial acumen and experience managing multimillion-dollar technology budgets.
  • Excellent communication, executive presence, and ability to influence across all organizational levels.
  • A bachelor's degree in information systems, computer science, or a related discipline is required.
Responsibilities
  • Define and own the Enterprise Architecture Vision and Roadmap aligned with business priorities, cost discipline, and global scalability.
  • Establish and maintain an Enterprise Reference Architecture integrating ERP, Command Center, aviation, digital, and data platforms within secure and efficient architectural frameworks.
  • Lead modernization initiatives using cloud-native services, application programming interfaces, automation, and microservices.
  • Translate strategic objectives into actionable architecture blueprints with business and functional leaders.
  • Drive architectural consistency and standardization across multi-cloud and on-premises environments.
  • Partner with cybersecurity and compliance teams to ensure designs adhere to information security and regulatory requirements.
  • Lead and manage the 24x7 Global Service Desk and infrastructure operations teams.
  • Ensure 99.999% uptime for critical business systems, including Command Center and manufacturing systems.
  • Oversee the design, deployment, monitoring, and maintenance of cloud and on-premises infrastructure.
  • Implement and maintain observability and monitoring frameworks for proactive system reliability and performance management.
  • Drive continuous improvement in service delivery, automation, and cost efficiency through data-driven operational reviews.
  • Establish operational key performance indicators and report performance to leadership.
  • Advise the CIO and senior leadership on architecture and infrastructure priorities.
  • Communicate complex technical strategies and trade-offs to non-technical audiences, including executives and board-level stakeholders.
  • Partner with regional and functional leaders in manufacturing, aviation, logistics, and digital functions to align IT capabilities with operational objectives.
  • Develop and manage the infrastructure and architecture budget.
  • Oversee vendor selection and performance management.
  • Lead due diligence and integration efforts for technology platforms during acquisitions and global expansion initiatives.
  • Define and enforce standards and policies for change management, infrastructure operations, and technology lifecycle management.
  • Lead and develop a global team of architects and infrastructure professionals.
  • Mentor and develop next-generation leaders across the IT organization.
  • Foster collaboration across IT, finance, operations, and digital functions.
  • Manage the Senior Manager, Cloud Infrastructure and Operations; Infrastructure Architect; and Application Architect positions on a daily basis.
Desired Qualifications
  • An MBA or advanced degree.
  • Experience leading large-scale digital or enterprise transformation initiatives within global, fast-scaling organizations.
  • Familiarity with enterprise architecture frameworks such as TOGAF or Zachman.
  • Experience supporting manufacturing or medical device operations with regulated systems.
  • Strong understanding of cybersecurity integration, data governance, and business continuity planning.

TransMedics makes the Organ Care System (OCS), a portable platform that keeps donor organs alive outside the body by warm, oxygenated perfusion and continuous viability monitoring. The OCS circulates warmed, nutrient-rich blood through the organ, allowing surgeons to assess health in near-physiological conditions. Revenue comes from selling OCS consoles, disposable sets used per procedure, and the National OCS Program, which provides end-to-end organ retrieval and logistics services. It distinguishes itself by holding FDA approvals to preserve and assess hearts, lungs, and livers in the United States and by integrating hardware, consumables, and logistics to expand transplant opportunities.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Andover, Massachusetts

Founded

1998

Get referred to TransMedics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $189.9 million, and management raised 2026 guidance on August 4.
  • April 23, 2026 CHOPS supports ENHANCE Heart and DENOVO Lung enrollment.
  • European PAD Aviation rollout starts a dedicated organ transport network across Europe.

What critics are saying

  • Judge Sorokin partially sustained the July 21, 2026 securities fraud case in Massachusetts.
  • Q2 2026 gross margin fell to 60%, while operating margin guidance dropped to 12.5%-14%.
  • A failed ENHANCE or DENOVO readout would freeze adoption and shatter TransMedics' premium story.

What makes TransMedics unique

  • FDA-approved OCS remains the only U.S. platform for hearts, lungs, and livers.
  • TransMedics' NOP bundles surgeons, logistics, and aircraft, locking in transplant-center workflows.
  • July 6, 2026 PAD Aviation investment exports the NOP model into Europe.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Short Term Disability

Long Term Disability

Health Savings Account/Flexible Spending Account

Dependent Care Flexible Spending Account

401(k) Plan

Pet insurance

Employee Stock Purchase Plan

Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
PR Newswire
Aug 4th, 2026
TransMedics reports 21% revenue growth to $190M in Q2 2026, raises guidance despite margin pressure

TransMedics Group reported second quarter 2026 revenue of $189.9 million, a 21% increase from $157.4 million in the prior year period. The growth was driven primarily by increased utilisation of the company's Organ Care System, particularly in liver and heart transplants through its National OCS Programme, as well as logistics services revenue. Gross margin decreased to 60% from 61% year-over-year, reflecting a higher mix of service revenue and temporary product-cost factors. Net income fell to $14.7 million, or $0.41 per diluted share, compared to $34.9 million, or $0.92 per share, in the second quarter of 2025. The company raised the low end of its full-year 2026 revenue guidance to a range of $737 million to $757 million, representing approximately 22% to 25% growth. TransMedics develops portable extracorporeal warm perfusion technology for donor organ transplantation.

MarketScreener
Jul 6th, 2026
TransMedics invests in PAD Aviation to build Europe-wide organ transplant air logistics network

TransMedics Group has completed a strategic investment in PAD Aviation service GmbH, a Germany-based private aviation operator. The deal aims to establish a dedicated organ transplantation air logistics network across Europe, replicating TransMedics' OCS NOP model from the US. PAD Aviation, founded in 2006, operates from a 24/7 hub in Paderborn, Germany. The company maintains a fleet of nine Embraer Phenom 300 aircraft and employs over 40 pilots, holding a valid EASA Air Operator Certificate. TransMedics develops portable extracorporeal warm perfusion technology for preserving and assessing donor organs. The investment supports the company's efforts to expand adoption of its OCS perfusion technology and create a pan-European organ transport logistics network across the European Union.

Yahoo Finance
Jul 2nd, 2026
TD Cowen sets $120 target on TransMedics, sees 77% upside on transplant growth

TransMedics Group has received a 'Buy' rating from TD Cowen with a $120 price target, implying 77% upside from its last close. The firm cited growing US transplant activity in heart, liver and lung procedures as a key driver for the company's Organ Care System technology and logistics business. Monthly US transplant data showed volumes rose approximately 5% year-over-year in the second quarter of 2026. TransMedics generated $173.9 million in total revenue in the first quarter of 2026, up 21% year-over-year, with product revenue reaching $108 million and service revenue contributing $66 million. The company ended the quarter with $461.7 million in cash and cash equivalents. Shares closed up 2% on Wednesday and gained further in after-hours trading.

Yahoo Finance
Jun 24th, 2026
TransMedics director sells $722K in stock after 45% share price decline

TransMedics Group director Thomas J. Gunderson sold 9,624 shares of common stock for approximately $722,000 in an options-related transaction, according to an SEC Form 4 filing. The sale was executed immediately after exercising vested stock options, with proceeds used to cover the option exercise price and associated tax obligations. All shares were held and transacted directly by Gunderson, with no involvement from trusts or other indirect entities. Following the transaction, Gunderson's direct common share holdings are valued at approximately $1.26 million. The transaction appears to align with routine portfolio and liquidity management rather than a discretionary reduction in exposure, given its structure as an option exercise and sale to cover costs. TransMedics develops the Organ Care System for preserving and monitoring donor organs.

Yahoo Finance
May 7th, 2026
TransMedics and Rhythm Pharmaceuticals tipped as May stock bargains after sell-offs

Rhythm Pharmaceuticals, a healthcare stock that has declined year-to-date, is positioned for a rebound according to investment analysis. The drugmaker's shares have already begun recovering, with continued momentum expected. TransMedics Group, developer of the Organ Care System technology for donor organ transport, has seen shares fall sharply despite strong long-term prospects. The company reported first-quarter 2026 revenue growth of 21% year-over-year, though operating expenses rose faster due to research and development investments. TransMedics is expanding into Europe and developing a kidney transplant system, which could significantly boost growth given kidneys represent 40% more transplants annually than hearts, lungs and livers combined. Both stocks are recommended as May buying opportunities for long-term investors.

INACTIVE